Philippe Reix

Also affiliated with Hôpital Femme Mère Enfant, Hospices Civils de Lyon

MedicineHealth ProfessionsNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial”.

Vanzacaftor–tezacaftor–deutivacaftor for children aged 6–11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial

The Lancet Respiratory Medicine(2025)10.1016/s2213-2600(24)00407-7

N/A

1.4DataRank · unranked

50 citations

Ajay S. Kasi, Jessica E. Pittman, Renée Jensen, L. Thia, Philip Robinson +44 more

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study

American Journal of Respiratory and Critical Care Medicine(2022)10.1164/rccm.202202-0392oc

N/A

0DataRank · unranked

141 citations

Rossa Brugha, Silvia Gärtner, Julian Legg, Alexander Mœller, Pedro Mondéjar-López +19 more